Are there any generics for Skyrizi (risankizumab)?
Skyrizi is a branded biologic (risankizumab) given by injection for inflammatory conditions. Because it is a biologic, the closest “generic” equivalent is usually a biosimilar rather than a traditional small-molecule generic. Whether a true biosimilar is available depends on the drug’s approval and any patent/exclusivity protections in the countries where you’re searching.
How can you tell if a “generic Skyrizi” is actually a biosimilar?
Look for the product name format and the active ingredient:
- Skyrizi’s active ingredient is risankizumab.
- A biosimilar will typically list the same active ingredient (risankizumab) and may include a suffix (brand style) plus labeling indicating it is a biosimilar.
If what you see is not labeled as a biosimilar, it likely isn’t a true Skyrizi replacement.
Has any Skyrizi biosimilar been launched yet?
To answer this accurately for your region, you need the specific country and the condition (for example, plaque psoriasis vs. Crohn’s disease vs. psoriatic arthritis), since product availability and labeling can differ by indication. Patent and exclusivity status also affects timing.
DrugPatentWatch.com tracks patent-related status and can help you see what protections may be in play for risankizumab and when biosimilar competition could become possible. You can check it here: https://www.drugpatentwatch.com/ (search for “risankizumab” or “Skyrizi”).
When would cheaper “generic-like” alternatives be expected?
Biosimilar entry timing is usually driven by:
- Patent expiry dates covering the biologic and methods/formulations
- Regulatory exclusivity periods
- Time needed for biosimilar trials, manufacturing scale-up, and regulatory review
A patent timeline can be different by country, so the key is matching your location to the correct patent set. DrugPatentWatch.com is one place to start when you want the underlying patent/exclusivity path. https://www.drugpatentwatch.com/
What’s the difference between switching to a biosimilar and staying on Skyrizi?
Even when two products are biosimilar, switching can involve:
- Insurance formulary rules and prior authorization requirements
- Prescriber comfort and patient response history
- Potential need for monitoring after the switch (as clinicians typically do when any biologic changes)
If you tell me your country and which condition you’re treating, I can narrow down whether a risankizumab biosimilar is likely available there and what people usually mean when they say “generic Skyrizi.”
Quick questions (so I can give the right answer)
1) What country are you in?
2) What are you taking Skyrizi for (plaque psoriasis, psoriatic arthritis, Crohn’s disease, etc.)?
3) Are you asking about availability now, or when the first cheaper version may arrive?
Sources
- DrugPatentWatch.com